Cellular Biomedicine Group Inc. announced the signing of a ten-year lease of a 113,038 square feet building located in the “Pharma Valley” in Shanghai Zhangjiang High-Tech Park. The new GMP facility that will be built on these premises will consist of 40,000 square feet dedicated to advanced cell manufacturing. By the end of 2017, the Company anticipates that the new Zhangjiang, an expanded Wuxi, and Beijing GMP facilities combined will have 70,000 square feet, and the Company expects that it will be capable of supporting simultaneous clinical trials for five different CAR-T and stem cell products, or approximately the ability to treat 10,000 cancer patients and 10,000 stem cell patients per year.